HUBUNGAN HBA1C DENGAN TRIGLISERIDA, LDL-K DAN APO B PADA PENDERITA DM DENGAN KOMPLIKASI JANTUNG KORONER - Diponegoro University | Institutional Repository (UNDIP-IR)

DAFTAR PUSTAKA

1. Karam JH, Forsham. Hormon-hormon pankreas dan diabetes melitus. In:
Greenspan FS, Baxter, editors. Endokrinologi dasar dan klinik. 4th ed.
Jakarta: EGC; 2000.
2. German MS, Masharani. Pancreatic hormones and diabetes mellitus. In:
Gardner

DG,

Shoback D, editors. Greenspans basic

and clinical

endocrinology. 8th ed. America: McGraw Hill, Companies; 2004. p. 661-747.
3. Laakso M. Cardiovaskular disease in type 2 diabetes from population to man
to mechanisms. Diabet Care 2010;33(2):442-9.
4. PERKENI, editor. Konsensus : pengelolahan dan pencegahan diabetes melitus
tipe 2 di Indonesia 2011. Jakarta: PERKENI; 2011.
5. Meydani PYD. Faktor-faktor yang berhubungan dengan upaya pencegahan
komplikasi DM oleh pasien DM di poliklinik khusus peyakit dalam RSUP dr.

M. Djamil Padang. FK Andalas Padang 2011.
6. Supriyono M, Suharyo, Sugiri. Faktor-faktor risiko yang berpengaruh
terhadap kejadian penyakit jantung koroner pada kelompok usia kurang 45
tahun (studi kasus di RSUP dr Kariadi dan RS Telogorejo). Semarang:
UNDIP; 2008.
7. Johnstone MT, Veves A. Diabetes and cardiovascular disease. 2nd ed. New
Jersey: Humana Press; 2005.
8. Ismail H, Hanafiah M, Saadiah S, Tahir A, Huda Z, Yunus M. Control of
glycosylated haemoglobin (HbA1c) among type 2 diabetes mellitus patients
attending an urban health clinic in Malaysia. MHSJ 2011;9:58-65.
9. Josten S, Mutmainnah, Hardjoeno. Profil lipid penderita diabetes melitus tipe
2. IJCPML;13(1):20-2.

64

10. Soegondo S. Farmakoterapi pada pengendalian glikemia DM tipe 2. In:
Sudoyo AW, Setiyohadi, Alwi I, Simandibrata M, Setiati, editors. Buku ajar:
ilmu penyakit dalam. 5th ed. Jakarta: InternaPublishing; 2009. p. 1884-90.
11. Jabeen F, Rizvi HA, Aziz F, Akhtar Y. Effect of glycemic control on lipid
profile, platelet indices and antioxidant enzymes ( catalase and superoxide

dismutase ) activities in type 2 diabetics. IJAR 2013;1(7):207-15.
12. Momin AA, Banker MP, Bhoite GM. Glycosylated (HbA1C) : association
with dyslipidemia and predictor of cardiovascular diseases in type 2 diabetes
mellitus patients. IJHSR 2013;3(8):40-6.
13. Hessin SS, Abdrabo EA. Measurement of plasma triglyceride and total
cholesterol in sudanese patients with controlled and uncontrolled type 2
diabetes. IJIAR 2014;2(2):47-50.
14. Holvoet P, de Keyzer D, Jacobs D. Oxidized LDL and the metabolic
syndtome. Future lipidol 2008;3(6):637-49.
15. Ekawati ER. Hubungan kadar glukosa darah terhadap hipertrigliserida pada
penderita diabetes mellitus. Seminar nasional kimia UNESA Surabaya 2012.
16. Cleland SJ. Cardiovascular risk in double diabetes mellitus when two worlds
collide. Nat.Rev Endocrinol 2012;8:476-85.
17. Bays HE, Toth PP, Kris-Etherton PM, Abate N, Aronne LJ, Brown WV, et al.
Obesity, adiposity, and dyslipidemia: A consensus statement from the
National Lipid Association. JCL 2013;7(4):233-9.
18. Pushparaj JL, Kirubakaran S. HbA1C as a predictor of lipid profile in type 2
diabetic patients. JEMDS 2014;3(12):3157-65.
19. Little RR, Sacks DB. HbA1C : How do we measure it and what does it mean.
Curr Opin Endocrinol Diabetes Obes 2009;16:113-8.

20. Christy AL, Manjrekar PA, Babu RP, Hegde A. Influence of iron deficiency
anemia on hemoglobin A1C levels in diabetic individuals with controlled
plasma glucose levels. IBJ 2014;18(2):88-93.
65

21. Charitha, Senghor A, Shivashekar M, William E. Glycated Hemoglobin as a
dual marker: in control of glycemia status and diabetic dyslipidemia. IJPCR
2013;5(3):111-3.
22. Sasisekhar TVD, Shabana S. Can HbA1c act as a surrogate marker for
cardiovascular risk. JDMS 2013;3(4):39-43.
23. Singh P, Arumalla VK, Rajagopalan B. Comparison of lipid profile between
controlled and uncontrolled type 2 diabetic subjects. JMHS 2013;2(4):69-72
24. Senghor A, William E. Correlation of HBA1C and non HDL cholesterol to
assess diabetic dyslipidemia. IJRSR 2014;5(5):931-3.
25. Pujari SS. HbA1C as marker of dyslipedemia in type 2 diabetes mellitus
patients. SJAMS 2013;1(6):728-31.
26. Bodhe C, Jankar D, Bhutada T, Patwardhan M, Patwardhan MV. HbA1C:
predictor of dyslipiemia and atherogenicity in diabetes mellitus. IJBMS
2011;2(5):278-82.
27. Songa RM. Lipid profile in type 2 DM with obesity. BOPAMS

2013;1(2):132-8.
28. Ugwu CE, Ezeanyika LUS, Daikwo MA, Amana R. Lipid profil of diabetic
patients attending Nigerian National Petroleum Corporation Clinic, Abuja.
AJBR 2009;3(3):66-9.
29. Otamere HO, Aloamaka CP, Okokhere PO, Adisa WA. Lipid profil in
diabetes meliitus; What impact has age and duration. BJPT 2011;2(3):135-7.
30. Siddiqui IA, Laxmikanth B, Mariya, Rao R. Lipid indices in type II diabetes
mellitus and their association with macro and micro vascular complications.
IJMRHS 2012;2(1):87-92.
31. Khan HA. Clinical significance of HbA1C as a marker of circulating lipids in
male and female type 2 diabetic patients. Acta Diabetol 2007;2:1-5

66

32. Loei GSC, Pandelaki K, Mandang V. Hubungan kadar HbA1C dengan profil
lipid pada penderita DM tipe 2 di poliklinik endokrin dan metabolic RSUP
Prof. dr. R. D. Kandou Manado. IPD FK Sam Ratulangi Manado 2013.
33. Hasan H, Isnanta R. Hubungan mikroalbuminuria dengan penyakit jantung
koroner. Departemen Kardiologi dan Kedokteran vaskuler FK-USU/RS H.
Adam Malik Medan. MKN 2006;39(3):239-42.

34. Garg N, Agrawal YB, Gupta S. A study of lipid profile levels in diabetics and
non-diabetics taking TC/HDL ratio consideration. JIACM 2014;15(3-4):1925.
35. Gomes MB, Giannella-Neto, Faria M, Tambascia M, Fonseca RM, Rea R et
al. Estimating cardiovascular risk in patients with type 2 diabetes: a national
multicenter study in Brazil. Diabetol Metab Syndr 2009;1(22):1-7.
36. Wilson PWF. Lipids and vascular disease: a framinghan perspective. Global
Heart 2013;8(1):25-33.
37. Chan DC, Watts. Apolipoprotein as marker and managers of coronary risk. QJ
Med 2006;99:277-87.
38. Mallick AK, Maradi R, Joshi VR, Bhat G. A study on apo B100/apo A-I ratio
in uncontrolled type 2 diabetes mellitus. IJABPT 2011;2(1):379-84.
39. Ali MK, Narayan KMV, Tandon N. Diabetes and coronary heart disease:
current perspective. IJMR 2010;132:584-97.
40. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV et al.
Diabetes and cardiovaskuler disease a statement for healthcare professionals
from the American heart association. Circulation 1999;100:1134-45.
41. Meenu J, Jayendrasinh J, Neeta M. Correlation between HbAC values and
lipid profile in type 2 diabetes mellitus. IJBAP ;2(1):47-50.
42. Chiha M, Njeim M, Chedrawy EG. Diabetes and coronary heart disease: a
risk factor for the global epidemic. IJH 2012:1-7.

67

43. Tripathi BK, Srivastava AK. Diabetes mellitus : complications and
therapeutics. MSM 2006;12(7):130-47.
44. Bartels DW, Davidson MH, Gong WC. Type 2 diabetes and CV
cardiovascular disease: reducing the risk. JMCP 2007;13(2):1-15.
45. Khawlani AA, Atef ZA, Al-Ansi. Macrovascular complications and their
associated risk factor in type 2 diabetic patients in Sana city Yemen. EMHJ
2010;16(8):851-8.
46. Sungkar MA. Diagnosis dan stratifikasi risiko sindroma koroner akut. In:
Sungkar MA, Rifqi S, editors. One day course: penanganan sindroma koroner
akut secara paripurna. Semarang: PERKI cab Semarang.
47. Herminingsih S, Uddin I, Tanuwidjojo. Patogenesis penyakit kardiovaskuler
pada diabetes melitus. In: Darmono, Suhartono T, Pemayun TGD,
Padmomartono FS, editors. Naskah lengkap: diabetes melitus ditinjau dari
berbagai aspek penyakit dalam, dalam rangka purna tugas prof dr RJ
Djokomoeljanto. Semarang: UNDIP; 2007. p. 245-56.
48. Strom JB, Libby P. Atherosclerosis. In: Lilly LS, editor. Pathophysiology of
heart disease. 5th ed. Philadelphia: William L, Wilkins; 2011. p. 113-34.

49. Djokomoeljanto. Neuropati diabetik. In: Darmono, Suhartono T, Pemayun
TGD, Padmomartono FS, editors. Naskah lengkap : diabetes melitus ditinjau
dari berbagai aspek penyakit dalam, dalam rangka purna tugas prof dr RJ
Djokomoeljanto. Semarang: UNDIP; 2007. p. 1-14.
50. Baraas

F.

Kardiologi

molekuler

radikal

bebas:

disfungsi

endotel,

aterosklerosis, antioksidan, latihan fisik dan rehabilitasi jantung. Jakarta.
Kardia Igratama. 2006. p. 447.
51. Hadi HAR, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc
Health Risk Manag 2007;3(6):853–76.
52. Peppa M, Vlassara H. Advanced glycation end products and diabetic
complications: a general overview. Hormones 2005;4(1):28-37.
68

53. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis:
molecular mechanisms. Cardio diabet 2002;1:1-10.
54. Oliveira MIA, Souza EM, Pedrosa FDO, Rea RR, Alves ADSC, Picheth G, et
al. RAGE receptor and its soluble isoforms in diabetes mellitus complications.
J Bras Patol Med Lab 2013;49(2):97-108.
55. Creager MA, Lüscher TF, Cosentino F, Becman JA. Diabetes and vascular
disease pathophysiology, clinical consequences, and medical therapy: Part I.
Circulation 2003;108:1527-32.
56. Buse JB, Polonsky KS, Burant CF. Type 2 diabetes mellitus. In: Kronenberg
HM, Melmed S, Polonsky KS, Larsen PR, editors. Williams textbook of
endocrinology. 11th ed. Canada: Elsevier; 2008. p. 1329-89.
57. Suryaatmadja M. Standarisasi dan harmonisasi pemeriksaan HbA1C. In:

Oesman editor. Pendidikan berkesinambungan Patologi Klinik 2010. Jakarta:
Patologi Klinik FK UI; 2010. p. 92-104.
58. Sheikh SA, Baig JA, Iqbal T, Kazmi T, Baig M, Husain SS. Prevalence of
microalbuminuria with relation to glycemic control in type 2 diabetic patiens
in Karachi. J Ayub Med Coll Abbottabad 2009;21(3):83-7.
59. Kurnianingsih S, Widyastuti P, Cahyaningrum R, Rahayu S. Pedoman
pemeriksaan laboratorium dan diagnostik. In: Kapoh RP editor. Laboratory
and diagnostic tests with nursing implications. Kee JL. 6th ed. Jakarta: EGC;
2008.
60. Chandalia HB, Krishnaswamy PR. Glycated hemoglobin. Curr Sci 2002
;83(12):1522-32.
61. Thakur S, Chauhan V, Negi RC. Role of HbA1C in Diabetes Mellitus.
JIACM 2009;10(2):52-4.
62. Nitin S. HbA1C and factors other than diabetes mellitus affecting it.
Singapore Med J 2010;51(8): 616-22.

69

63. Yamagishi SI, Nakamura K, Imaizumi T. Advanced glycation end products
(AGEs) and diabetic vascular complications. Curr Diabetes Rev 2005;1:93106.

64. Sinha N, Mishra TK, Singh T, Gupta N. Effect of iron deficiency anemia on
hemoglobin A1C levels. Ann Lab Med 2012;32:17-22.
65. Chu CH, Wang MC, Sun TH, Lee JK, Lam HC. Very low HbA1C values
patient with clnical silent hemoglobin variant (hemoglobin J)-a case report. J
Intern Med Taiwan 2007;18:45-50.
66. Ford ES, Cowie CC, Chaoyang, Handelsman Y, Bloomgarden. Iron
deficiency anemia, non iron deficiency anemia and HbA1C among adults in
the US. J Diab 2011;3:67-73.
67. Suryaatmadja M. Peran pemeriksaan kadar HbA1C untuk diagnosis
pradiabetes.

In:

Timan

IS,

Wulandari

D,

editors.

Pendidikan

berkesinambungan Patologi Klinik 2013. Jakarta: Patologi Klinik FK UI;
2013. p. 57-70.
68. Frida ME, Diah MI. Pemeriksaan HbA1C secara ion exchange HPLC.
Surakarta: Patologi Klinik FK UNS; 2012.
69. Banerjee. HbA1C result, does it depend upon the testing method. JAPI
2014;62:9-12.
70. Adam JMF. Dislipidemia. Dalam:

Sudoyo AW, Setiyohadi, Alwi I,

Simandibrata M, Setiati, editors. Buku ajar ilmu penyakit dalam. 5th ed.
Jakarta: InternalPublishing; 2009. p. 1984-92.
71. Anonim. Pengertian kolester. Available from: URL:
http://sulegratis.blogspot.com/2012/12/pengertian-kolesterol.html Cited 2014
Sep 20.
72. Burts C, Ashwood E, Bruns D. Tiets texbook of clinical chemistry and
molecular diagnostic. 5th ed. United State of America: Elsevier saunders;
2012 p. 744.
70

73. Nugroho HSW. Metabolisme lipid. Available from: URL:
Zaifbio.wordpress.com/2010/06/02/metabolisme-lipid. Cited 2013 Aug 15.
74. Tomkin GH, Owens D. LDL as a cause of atherosclerosis. Atheroscler
Thromb J 2012;5:13-21.
75. Anonim. Lipoproteins: Lipid Digestion & Transport. Available from:
URL:https://www.rpi.edu/dept/bcbp/molbiochem/MBWeb/mb2/part1/lipoprot
.htm. Cited 2014 Oct 2.
76. Raja RP, Jayarama N, Shashidhar KN. Association among HbA1C and lipid
profile in kolar type 2 diabetic population. JPSI 2013;2(6):10-2.
77. Berneis K, Rizzo M. LDL size : does it matter? In mini review. Swiss Med
Wkly 2004;134:720-4.
78. Suhartono T. Dislipidemia pada diabetes melitus. In: Darmono, Suhartono T,
Pemayun TGD, Padmomartono FS, editors. Naskah lengkap : diabetes melitus
ditinjau dari berbagai aspek penyakit dalam, dalam rangka purna tugas prof dr
RJ Djokomoeljanto. Semarang: UNDIP; 2007. p. 31-50.
79. Zylbeari L, Zylberai G, Bexheti Z. Concentration of apolipoprotein B100
(Apo B100) and lipoprotein a (Lpa) at patients with diabetes mellitus. IJSER
2014;5(11):103-16.
80. Dixon JL, Biddle J, Lo CM, Stoops JD, Li H, Sakata N, Philip TE.
Apolipoprotein B is synthesized in selected human non-hepatic cell lines but
not

processed

into

mature

lipoprotein.

J

Histochem

Cytochem

2002;50(5):629-39.
81. Ramjee V, Sperling LS, Jacobson TA. Non high density lipoprotein
cholesterol versus apolipoprotein B in cardiovascular risk stratification. J Am
Coll Cardiol 2011;58(5):457-63.
82. Segrest JP, Jones MK, Loof HD, Dashti N. Structure of apolipoprotein B-100
in low density lipoproteins. J. Lipid Res 2001;42:1346-66.

71

83. Fisher WR, Zech LA, Stacpoole PW. Apo B Metabolism in familial
hypercholesterolemia inconsistencies with the LDL receptor paradigm.
Aterioscler Thromb 2015;14(4):501-10.
84. Olofsson SO, Boren J. Apolipoprotein B secretory regulation by degradation.
Aterioscler Thromb Vasc Biol 2012;32:1334-8.
85. Kwiterovich PO. Lipoprotein Heterogeneity: Diagnostic and therapeutic
implications. Am J Cardiol 2002;90(8):1-10.
86. Wallach J. Interpretation of diagnostic tests. 7th ed. Philadelphia: Lippincott
Williams and Wilkins; 2000. p. 41.
87. Pasca.unand.

Hubungan

glycosylated

haemoglobin

terhadap

kadar

adiponektin dan kadar trigliserida pada diabetes mellitus tipe 2. Available
from: URL:Pasca.unand.ac.id/ad/wp-content/uploads/2011/09/. Cited 2014
Sep 20.
88. Grundy SM. Hypertrigliseridemia, insulin resistance, and the metabolic
syndrome. Am J Cardiol 1999;83:25-9.
89. Clare-Salzler MJ, Crawford JM, Kumar V. Pankreas. In: Kumar V, Citran RS,
Robbins SL, editors. Robbins basic pathology. 7th ed. Jakarta: EGC; 2007.
90. Tomkin

GH.

Hyperglycaemia:

the

relation

to

dyslipidaemia

and

atherosclerosis. Ir J Med Sci ;171(3);161-4.
91. Isoma B. Cronic diabetic complication in clinically, immunologically and
genetically defined subgroups. Helsinki 2001. p 15.
92. Prabhavathi K, Kunikullaya K, Goturu J. Glycosylated haemoglobin (HbA1C)
a marker of circulating lipids in type 2 diabetic patients. Curr Diabetes Rev
2014;8(2):20-3.
93. Wang X, Bucala R, Milne R. Epitopes close to the apolipoprotein B low
density lipoprotein receptor binding site are modified by advanced glycation
end products. Med Scien 2008;95:7643-7.

72

94. Sastroasmoro S. Dasar-dasar metodologi penelitian klinis. 3rd ed. Jakarta:
Sagung Seto; 2007.
95. Dahlan MS. Seri evidence based medicine : besar sampel dalam penelitian
kedokteran kesehatan. Jakarta: PT ARKANS; 2006. p. 25, 67.
96. Hastono SP. Basic data analysis for health research training: analisis data
kesehatan. Depok: FKM UI; 2007.
97. Yuliani F, Oenzil F, Iryani D. Hubungan berbagai faktor risiko terhadap
kejadian penyakit jantung koroner pada penderita diabetes melitus tipe 2. JKA
2004;3(1):37-40.
98. Tarcin O, Uluganyan M, Tartan Z, Yekeler I. Glycemic profiles and their
diagnostic value among inpatients in a cardiology clinic. Endocrinol Metab
Synd 2012;5:1-5.
99. McDermott RA, McCulloch B, Li M. Glycaemia and albuminuria as
predictors of coronary heart disease in Aboriginal and Torres Strait Islander
adults: a north Queensland cohort. MJA 2011;194:514–8.
100. Singh G, Kumar A. Relationship among HbA1C and lipid profile in Punajbi
type 2 diabetic population. JESP 2011;7(2):99-102.
101. Vinodmahato R, Gyawali P, Raut PP, Regmi P, Singh KP, Pandeya D et al.
Association between glycaemi control and serum lipid profil in type 2 diabetic
patients: Glycated haemoglobin as adual biomarker. Biomed Research
2011;22(3):375-80.
102. Samatha P, Prabodh S, Chowdar NVS, Shekhara. Glycated hemoglobin and
serum lipid profile associations in type 2 diabetes Mellitus patients. JPBSMS
2012;17(12):1-4.
103. Yathish TR, Annamalai N, Shankar V. Association of low density
lipoprotein levels and glycaemic control in type 2 diabetes mellitus. Electron
Physician 2010;(2):24-32.

73

104. Reddy R, Jayarama N, Shashidhar KN. Association among Hba1C and lipid
profile in kolar type 2 diabetic population. JPSI 2013;2(6):10-12.
105. Aboelela MI, Elmajeed ADA, Elmaksoud HA, Sayed AA. A study on apo
B/apo A1 ratio as a predictive parameter for assessmen of CAD risk in
uncountrolled type 2 egyptian diabetic patients. EJHM 2014;54:62-70.
106. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I : risk
indicator of coronary heart disease and targets for lipid modifying therapy. J
Intern Med 2004;255:188-205.

74